Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
三十五味达西丸 (Sanshiwu Wei Daxi Wan) is a traditional Tibetan medicine formulated as an oral pill, developed and manufactured by Qinghai Jiumei Tibetan Medicine Co., Ltd. This complex herbal formulation consists of 35 ingredients, including Terminalia chebula, Terminalia bellirica, and Phyllanthus emblica, among others. It is traditionally indicated for the treatment of chronic hepatitis, liver cirrhosis, and gallbladder disorders. In the context of Tibetan medicine, it is used to clear heat, detoxify the liver, and promote bile flow. The product is officially approved in China (NMPA) under the drug approval number 国药准字Z20023285, signifying its status as a marketed pharmaceutical product rather than a dietary supplement.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 三十五味达西丸.